Benchmark Reiterates Buy on Medicine Man Technologies, Maintains $2.5 Price Target
Portfolio Pulse from Benzinga Newsdesk
Benchmark analyst Mike Hickey has reiterated a Buy rating on Medicine Man Technologies (OTC:SHWZ) and maintained a price target of $2.5.
August 14, 2024 | 2:29 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Benchmark analyst Mike Hickey has reiterated a Buy rating on Medicine Man Technologies (OTC:SHWZ) and maintained a price target of $2.5.
The reiteration of a Buy rating and the maintenance of a $2.5 price target by a reputable analyst is likely to positively impact investor sentiment and could lead to a short-term increase in the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100